Glimepiride
Generic Name: Glimepiride
Therapeutic Class: Second Generation Sulfonylurea (Antidiabetic)
Indications
Glimepiride is an oral blood-glucose-lowering drug indicated for the management of Type 2 Diabetes Mellitus (T2DM):
- Monotherapy: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
- Combination Therapy: May be used in combination with Metformin or Insulin when diet, exercise, and monotherapy do not result in adequate glycemic control.
- Secondary Failure: Indicated for patients who have lost responsiveness to other sulfonylureas.
Dosage & Administration
The dosage of Glimepiride must be individualized to achieve the target blood glucose level.
- Initial Dose: 1 mg to 2 mg once daily. For patients sensitive to hypoglycemic drugs, the starting dose should be 1 mg.
- Maintenance Dose: The usual maintenance dose is 1 mg to 4 mg once daily. The maximum recommended dose is 8 mg once daily.
- Administration: It should be taken with breakfast or the first main meal of the day. It is crucial not to skip meals after taking the dose.
- Titration: Dosage increases should be made in increments of no more than 2 mg at 1-2 week intervals based on blood glucose response.
Description & Pharmacokinetics
Glimepiride is a long-acting sulfonylurea that stimulates the pancreas to produce more insulin.
Mechanism of Action: Glimepiride lowers blood glucose by stimulating the release of insulin from **functioning pancreatic beta cells**. It binds to a specific 65 kDa protein in the beta-cell membrane, which leads to the closure of **ATP-sensitive potassium ($K_{ATP}$) channels**. This triggers depolarization, opening of voltage-gated calcium channels, and subsequent exocytosis of insulin. It also possesses "extrapancreatic" effects, such as increasing the sensitivity of peripheral tissues to insulin.
Pharmacokinetics:
Mechanism of Action: Glimepiride lowers blood glucose by stimulating the release of insulin from **functioning pancreatic beta cells**. It binds to a specific 65 kDa protein in the beta-cell membrane, which leads to the closure of **ATP-sensitive potassium ($K_{ATP}$) channels**. This triggers depolarization, opening of voltage-gated calcium channels, and subsequent exocytosis of insulin. It also possesses "extrapancreatic" effects, such as increasing the sensitivity of peripheral tissues to insulin.
Pharmacokinetics:
- Absorption: Completely absorbed (100% bioavailability) after oral administration.
- Protein Binding: Highly protein-bound (>99.5%), primarily to albumin.
- Metabolism: Completely metabolized in the liver via **CYP2C9** to two main metabolites.
- Excretion: Approximately 60% is excreted in the urine and 40% in the feces. The half-life is about 5 to 9 hours, allowing for once-daily dosing.
Side Effects
- Hypoglycemia: The most common and serious side effect. Symptoms include dizziness, sweating, hunger, and tremors.
- Gastrointestinal: Nausea, vomiting, and epigastric pain.
- Dermatological: Pruritus, erythema, and urticaria.
- Visual: Temporary visual impairment (blurred vision) may occur at the start of treatment due to changes in blood glucose levels.
- Hematologic: Rarely, leukopenia, agranulocytosis, or hemolytic anemia.
Extra Important Information: Usage Insights
- Alcohol Warning: Alcohol can increase the hypoglycemic effect of Glimepiride and may cause a disulfiram-like reaction.
- Stress Management: During periods of stress (fever, trauma, infection, or surgery), glycemic control may be lost, and it may be necessary to switch to Insulin.
- Hypoglycemia Treatment: Patients should always carry a source of fast-acting sugar (like glucose tablets or fruit juice) to treat mild hypoglycemia.
- Weight Change: Sulfonylureas are generally associated with modest weight gain.
Pregnancy & Lactation
- Pregnancy: Category C. Glimepiride is generally contraindicated during pregnancy; Insulin is the drug of choice to control blood glucose in pregnant women.
- Lactation: It is excreted in rat milk. It is not recommended for nursing mothers as there is a significant risk of hypoglycemia in the infant.
Storage
Store at a temperature below 30°C in a dry place. Protect from light. Keep the medicine out of the reach of children.
.png)
